Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources sayReuters • 04/22/26
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPRNewsWire • 04/21/26
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPRNewsWire • 04/20/26
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, TooSeeking Alpha • 01/13/26
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) ProgramPRNewsWire • 12/16/25
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion CohortsPRNewsWire • 10/23/25
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion CohortsPRNewsWire • 10/22/25
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentPRNewsWire • 04/01/25
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal CancerPRNewsWire • 01/21/25
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformSeeking Alpha • 11/05/24
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationPRNewsWire • 11/04/24
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are BuyingBenzinga • 08/27/24